CN112166099A - 新型HIF-1α抑制剂、其的制备方法以及包含其作为有效成分的用于预防或治疗新生血管相关性眼部疾病的药学组合物 - Google Patents
新型HIF-1α抑制剂、其的制备方法以及包含其作为有效成分的用于预防或治疗新生血管相关性眼部疾病的药学组合物 Download PDFInfo
- Publication number
- CN112166099A CN112166099A CN201980035213.9A CN201980035213A CN112166099A CN 112166099 A CN112166099 A CN 112166099A CN 201980035213 A CN201980035213 A CN 201980035213A CN 112166099 A CN112166099 A CN 112166099A
- Authority
- CN
- China
- Prior art keywords
- compound
- pharmaceutically acceptable
- group
- pharmaceutical composition
- straight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 17
- 208000030533 eye disease Diseases 0.000 title claims abstract description 15
- 239000004480 active ingredient Substances 0.000 title abstract description 13
- 238000004519 manufacturing process Methods 0.000 title abstract description 4
- OJYIBEYSBXIQOP-UHFFFAOYSA-N 1-methoxy-4-[2-(4-methoxyphenyl)propan-2-yl]benzene Chemical compound C1=CC(OC)=CC=C1C(C)(C)C1=CC=C(OC)C=C1 OJYIBEYSBXIQOP-UHFFFAOYSA-N 0.000 title abstract description 3
- 150000001875 compounds Chemical class 0.000 claims abstract description 91
- 206010029113 Neovascularisation Diseases 0.000 claims abstract description 20
- 102100032742 Histone-lysine N-methyltransferase SETD2 Human genes 0.000 claims abstract description 16
- 101000654725 Homo sapiens Histone-lysine N-methyltransferase SETD2 Proteins 0.000 claims abstract description 16
- 150000003839 salts Chemical class 0.000 claims description 26
- 239000000126 substance Substances 0.000 claims description 22
- 125000003545 alkoxy group Chemical group 0.000 claims description 14
- 230000002401 inhibitory effect Effects 0.000 claims description 13
- 239000012453 solvate Substances 0.000 claims description 11
- 230000003287 optical effect Effects 0.000 claims description 10
- 125000000217 alkyl group Chemical group 0.000 claims description 9
- 229910052736 halogen Inorganic materials 0.000 claims description 9
- 150000002367 halogens Chemical class 0.000 claims description 9
- 125000003282 alkyl amino group Chemical group 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 7
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 5
- 239000003085 diluting agent Substances 0.000 claims description 5
- 125000005842 heteroatom Chemical group 0.000 claims description 5
- 208000002780 macular degeneration Diseases 0.000 claims description 5
- 229910052757 nitrogen Inorganic materials 0.000 claims description 5
- 229910052760 oxygen Inorganic materials 0.000 claims description 5
- 229910052717 sulfur Inorganic materials 0.000 claims description 5
- 208000010412 Glaucoma Diseases 0.000 claims description 4
- 208000022873 Ocular disease Diseases 0.000 claims description 4
- 206010038933 Retinopathy of prematurity Diseases 0.000 claims description 4
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 4
- 201000003142 neovascular glaucoma Diseases 0.000 claims description 4
- 239000003960 organic solvent Substances 0.000 claims description 3
- 125000000440 benzylamino group Chemical group [H]N(*)C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 description 33
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 30
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 26
- 235000019439 ethyl acetate Nutrition 0.000 description 15
- 238000005160 1H NMR spectroscopy Methods 0.000 description 14
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 14
- -1 aliphatic mono Chemical class 0.000 description 14
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 13
- 238000003818 flash chromatography Methods 0.000 description 12
- 239000000203 mixture Substances 0.000 description 12
- 239000000741 silica gel Substances 0.000 description 12
- 229910002027 silica gel Inorganic materials 0.000 description 12
- 206010021143 Hypoxia Diseases 0.000 description 11
- 239000003921 oil Substances 0.000 description 11
- 235000019198 oils Nutrition 0.000 description 11
- 239000002253 acid Substances 0.000 description 9
- 238000004896 high resolution mass spectrometry Methods 0.000 description 9
- 230000000052 comparative effect Effects 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 239000000796 flavoring agent Substances 0.000 description 7
- 235000019634 flavors Nutrition 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 6
- LJIOLYYSDVTJOY-UHFFFAOYSA-N [4-[2-(3,4-dimethoxyphenyl)propanoyl]-3-methoxyphenyl] trifluoromethanesulfonate Chemical compound FC(S(=O)(=O)OC1=CC(=C(C=C1)C(C(C)C1=CC(=C(C=C1)OC)OC)=O)OC)(F)F LJIOLYYSDVTJOY-UHFFFAOYSA-N 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 230000007954 hypoxia Effects 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- UQLMIMJHWAHTGP-UHFFFAOYSA-N 4-[[4-[2-(3,4-dimethoxyphenyl)propanoyl]anilino]methyl]benzonitrile Chemical compound COC=1C=C(C=CC=1OC)C(C(=O)C1=CC=C(C=C1)NCC1=CC=C(C#N)C=C1)C UQLMIMJHWAHTGP-UHFFFAOYSA-N 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- 238000005576 amination reaction Methods 0.000 description 4
- 230000033115 angiogenesis Effects 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 150000007524 organic acids Chemical class 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 3
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 3
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229940125782 compound 2 Drugs 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 235000013376 functional food Nutrition 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 235000005985 organic acids Nutrition 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 230000002207 retinal effect Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- WARLSYMMKLPRIE-UHFFFAOYSA-N 1-(4-bromophenyl)-2-(2-fluorophenyl)propan-1-one Chemical compound BrC1=CC=C(C=C1)C(C(C)C1=C(C=CC=C1)F)=O WARLSYMMKLPRIE-UHFFFAOYSA-N 0.000 description 2
- HQWOJSFVXVNYFF-UHFFFAOYSA-N 1-(4-bromophenyl)-2-(3,4-dimethoxyphenyl)propan-1-one Chemical compound BrC1=CC=C(C=C1)C(C(C)C1=CC(=C(C=C1)OC)OC)=O HQWOJSFVXVNYFF-UHFFFAOYSA-N 0.000 description 2
- GSVSELDKEYJGHJ-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-1-(4-hydroxy-2-methoxyphenyl)ethanone Chemical compound COC=1C=C(C=CC=1OC)CC(=O)C1=C(C=C(C=C1)O)OC GSVSELDKEYJGHJ-UHFFFAOYSA-N 0.000 description 2
- WHBMMWSBFZVSSR-UHFFFAOYSA-N 3-hydroxybutyric acid Chemical compound CC(O)CC(O)=O WHBMMWSBFZVSSR-UHFFFAOYSA-N 0.000 description 2
- RAHBTVBFKALZFV-UHFFFAOYSA-N C(C1=CC=CC=C1)NC1=CC(=C(C=C1)C(C(C)C1=CC(=C(C=C1)OC)OC)=O)OC Chemical compound C(C1=CC=CC=C1)NC1=CC(=C(C=C1)C(C(C)C1=CC(=C(C=C1)OC)OC)=O)OC RAHBTVBFKALZFV-UHFFFAOYSA-N 0.000 description 2
- LXNVPVUPIABPBB-UHFFFAOYSA-N C(C1=CC=CC=C1)NC1=CC=C(C=C1)C(C(C)C1=C(C=CC=C1)F)=O Chemical compound C(C1=CC=CC=C1)NC1=CC=C(C=C1)C(C(C)C1=C(C=CC=C1)F)=O LXNVPVUPIABPBB-UHFFFAOYSA-N 0.000 description 2
- GHLPYHYFMLKPRF-UHFFFAOYSA-N C1(CCCCC1)OC1=CC(=C(C=C1)C(C(C)C1=CC(=C(C=C1)OC)OC)=O)OC Chemical compound C1(CCCCC1)OC1=CC(=C(C=C1)C(C(C)C1=CC(=C(C=C1)OC)OC)=O)OC GHLPYHYFMLKPRF-UHFFFAOYSA-N 0.000 description 2
- HIULSNURCWQFIL-UHFFFAOYSA-N COC1=C(C=CC(=C1)OC)C(C(C)C1=CC(=C(C=C1)OC)OC)=O Chemical compound COC1=C(C=CC(=C1)OC)C(C(C)C1=CC(=C(C=C1)OC)OC)=O HIULSNURCWQFIL-UHFFFAOYSA-N 0.000 description 2
- ILNCTOPCXSAVKY-UHFFFAOYSA-N COC=1C=C(C=CC=1OC)C(C(=O)C1=C(C=C(C=C1)N(C)C)OC)C Chemical compound COC=1C=C(C=CC=1OC)C(C(=O)C1=C(C=C(C=C1)N(C)C)OC)C ILNCTOPCXSAVKY-UHFFFAOYSA-N 0.000 description 2
- OIDMAIVMDMYADI-UHFFFAOYSA-N COC=1C=C(C=CC=1OC)C(C(=O)C1=C(C=C(C=C1)N1CCCC1)OC)C Chemical compound COC=1C=C(C=CC=1OC)C(C(=O)C1=C(C=C(C=C1)N1CCCC1)OC)C OIDMAIVMDMYADI-UHFFFAOYSA-N 0.000 description 2
- BZOJKFHBSXBBAG-UHFFFAOYSA-N COC=1C=C(C=CC=1OC)C(C(=O)C1=C(C=C(C=C1)N1CCCCC1)OC)C Chemical compound COC=1C=C(C=CC=1OC)C(C(=O)C1=C(C=C(C=C1)N1CCCCC1)OC)C BZOJKFHBSXBBAG-UHFFFAOYSA-N 0.000 description 2
- IRMAECQTQCVIII-UHFFFAOYSA-N COC=1C=C(C=CC=1OC)C(C(=O)C1=C(C=C(C=C1)N1CCOCC1)OC)C Chemical compound COC=1C=C(C=CC=1OC)C(C(=O)C1=C(C=C(C=C1)N1CCOCC1)OC)C IRMAECQTQCVIII-UHFFFAOYSA-N 0.000 description 2
- PHXKXYLWRMXNSW-UHFFFAOYSA-N COC=1C=C(C=CC=1OC)C(C(=O)C1=C(C=C(C=C1)OCC)OC)C Chemical compound COC=1C=C(C=CC=1OC)C(C(=O)C1=C(C=C(C=C1)OCC)OC)C PHXKXYLWRMXNSW-UHFFFAOYSA-N 0.000 description 2
- XOWFRYMVSNBVIF-UHFFFAOYSA-N COC=1C=C(C=CC=1OC)C(C(=O)C1=CC=C(C=C1)N1CCCC1)C Chemical compound COC=1C=C(C=CC=1OC)C(C(=O)C1=CC=C(C=C1)N1CCCC1)C XOWFRYMVSNBVIF-UHFFFAOYSA-N 0.000 description 2
- WXXJMQHEDMUASV-UHFFFAOYSA-N COC=1C=C(C=CC=1OC)C(C(=O)C1=CC=C(C=C1)N1CCOCC1)C Chemical compound COC=1C=C(C=CC=1OC)C(C(=O)C1=CC=C(C=C1)N1CCOCC1)C WXXJMQHEDMUASV-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- UQILSDDZPHWQBW-UHFFFAOYSA-N FC1=C(C=CC=C1)C(C(=O)C1=CC=C(C=C1)N1CCCCC1)C Chemical compound FC1=C(C=CC=C1)C(C(=O)C1=CC=C(C=C1)N1CCCCC1)C UQILSDDZPHWQBW-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 229910002651 NO3 Inorganic materials 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 208000007135 Retinal Neovascularization Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 239000003708 ampul Substances 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 159000000007 calcium salts Chemical class 0.000 description 2
- 208000037976 chronic inflammation Diseases 0.000 description 2
- 230000006020 chronic inflammation Effects 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L magnesium sulphate Substances [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 229940049920 malate Drugs 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- HCSBTDBGTNZOAB-UHFFFAOYSA-N 2,3-dinitrobenzoic acid Chemical compound OC(=O)C1=CC=CC([N+]([O-])=O)=C1[N+]([O-])=O HCSBTDBGTNZOAB-UHFFFAOYSA-N 0.000 description 1
- XMYXLGQQQPSYCB-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-1-[2-methoxy-4-(methoxymethoxy)phenyl]ethanone Chemical compound COC=1C=C(C=CC=1OC)CC(=O)C1=C(C=C(C=C1)OCOC)OC XMYXLGQQQPSYCB-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- LFIWXXXFJFOECP-UHFFFAOYSA-N 4-(aminomethyl)benzonitrile Chemical compound NCC1=CC=C(C#N)C=C1 LFIWXXXFJFOECP-UHFFFAOYSA-N 0.000 description 1
- OBKXEAXTFZPCHS-UHFFFAOYSA-N 4-phenylbutyric acid Chemical compound OC(=O)CCCC1=CC=CC=C1 OBKXEAXTFZPCHS-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- AMRMHIWSDXURTK-UHFFFAOYSA-N FC1=C(C=CC=C1)C(C(=O)C1=C(C=C(C=C1)N1CCCCC1)OC)C Chemical compound FC1=C(C=CC=C1)C(C(=O)C1=C(C=C(C=C1)N1CCCCC1)OC)C AMRMHIWSDXURTK-UHFFFAOYSA-N 0.000 description 1
- DXTLYFHTIAJXLP-UHFFFAOYSA-N FC1=C(C=CC=C1)C(C(=O)C1=C(C=C(C=C1)NCC1=CC=C(C#N)C=C1)OC)C Chemical compound FC1=C(C=CC=C1)C(C(=O)C1=C(C=C(C=C1)NCC1=CC=C(C#N)C=C1)OC)C DXTLYFHTIAJXLP-UHFFFAOYSA-N 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-N Nitrous acid Chemical compound ON=O IOVCWXUNBOPUCH-UHFFFAOYSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical class [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
- ZZXDRXVIRVJQBT-UHFFFAOYSA-M Xylenesulfonate Chemical compound CC1=CC=CC(S([O-])(=O)=O)=C1C ZZXDRXVIRVJQBT-UHFFFAOYSA-M 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- YTIVTFGABIZHHX-UHFFFAOYSA-L acetylenedicarboxylate(2-) Chemical compound [O-]C(=O)C#CC([O-])=O YTIVTFGABIZHHX-UHFFFAOYSA-L 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- PZZYQPZGQPZBDN-UHFFFAOYSA-N aluminium silicate Chemical compound O=[Al]O[Si](=O)O[Al]=O PZZYQPZGQPZBDN-UHFFFAOYSA-N 0.000 description 1
- 229910000323 aluminium silicate Inorganic materials 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 235000019568 aromas Nutrition 0.000 description 1
- 159000000032 aromatic acids Chemical class 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 238000010000 carbonizing Methods 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- JOYKCMAPFCSKNO-UHFFFAOYSA-N chloro benzenesulfonate Chemical compound ClOS(=O)(=O)C1=CC=CC=C1 JOYKCMAPFCSKNO-UHFFFAOYSA-N 0.000 description 1
- KVSASDOGYIBWTA-UHFFFAOYSA-N chloro benzoate Chemical compound ClOC(=O)C1=CC=CC=C1 KVSASDOGYIBWTA-UHFFFAOYSA-N 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 150000001991 dicarboxylic acids Chemical class 0.000 description 1
- FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 229940050411 fumarate Drugs 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229940041476 lactose 100 mg Drugs 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 125000005341 metaphosphate group Chemical group 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- IZYBEMGNIUSSAX-UHFFFAOYSA-N methyl benzenecarboperoxoate Chemical compound COOC(=O)C1=CC=CC=C1 IZYBEMGNIUSSAX-UHFFFAOYSA-N 0.000 description 1
- 229940095102 methyl benzoate Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- DYUMLJSJISTVPV-UHFFFAOYSA-N phenyl propanoate Chemical compound CCC(=O)OC1=CC=CC=C1 DYUMLJSJISTVPV-UHFFFAOYSA-N 0.000 description 1
- 229940049953 phenylacetate Drugs 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- 229950009215 phenylbutanoic acid Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Chemical class 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- KCXFHTAICRTXLI-UHFFFAOYSA-N propane-1-sulfonic acid Chemical compound CCCS(O)(=O)=O KCXFHTAICRTXLI-UHFFFAOYSA-N 0.000 description 1
- UORVCLMRJXCDCP-UHFFFAOYSA-M propynoate Chemical compound [O-]C(=O)C#C UORVCLMRJXCDCP-UHFFFAOYSA-M 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- 208000004644 retinal vein occlusion Diseases 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 229940116351 sebacate Drugs 0.000 description 1
- CXMXRPHRNRROMY-UHFFFAOYSA-L sebacate(2-) Chemical compound [O-]C(=O)CCCCCCCCC([O-])=O CXMXRPHRNRROMY-UHFFFAOYSA-L 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 229910001961 silver nitrate Inorganic materials 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 150000003385 sodium Chemical class 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- GGCZERPQGJTIQP-UHFFFAOYSA-N sodium;9,10-dioxoanthracene-2-sulfonic acid Chemical compound [Na+].C1=CC=C2C(=O)C3=CC(S(=O)(=O)O)=CC=C3C(=O)C2=C1 GGCZERPQGJTIQP-UHFFFAOYSA-N 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- TYFQFVWCELRYAO-UHFFFAOYSA-L suberate(2-) Chemical compound [O-]C(=O)CCCCCCC([O-])=O TYFQFVWCELRYAO-UHFFFAOYSA-L 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- KKEYFWRCBNTPAC-UHFFFAOYSA-L terephthalate(2-) Chemical compound [O-]C(=O)C1=CC=C(C([O-])=O)C=C1 KKEYFWRCBNTPAC-UHFFFAOYSA-L 0.000 description 1
- ISIJQEHRDSCQIU-UHFFFAOYSA-N tert-butyl 2,7-diazaspiro[4.5]decane-7-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCCC11CNCC1 ISIJQEHRDSCQIU-UHFFFAOYSA-N 0.000 description 1
- 239000000892 thaumatin Substances 0.000 description 1
- 235000010436 thaumatin Nutrition 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 229940071104 xylenesulfonate Drugs 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
- C07C225/22—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
- C07C255/59—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton the carbon skeleton being further substituted by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
- C07C49/84—Ketones containing a keto group bound to a six-membered aromatic ring containing ether groups, groups, groups, or groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Ophthalmology & Optometry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
本发明涉及一种新型的HIF‑1α抑制剂、其的制备方法以及将包含其作为有效成分的用于预防或治疗新生血管相关性眼部疾病的药学组合物,本发明的一具体例所提供的实施例化合物优异地抑制HIF‑1α,因此,可以有效地用作用于预防或治疗新生血管相关性眼部疾病的药学组合物。
Description
技术领域
本发明涉及一种新型HIF-1α(Hypoxia-Inducible Factor 1α)抑制剂,其的制备方法以及包含其作为有效成分的用于预防或治疗新生血管相关性眼部疾病的药学组合物。
背景技术
新生血管生成(Angiogenesis)是指从现有血管生成新的血管的机制,是在正常的生理条件下几乎不会发生的经严格调节的现象,发生在受精卵的发育过程中胚胎发育时、成年人的情况下伤口愈合时、以及女性的生殖周期中生殖器系统的变化等中。
成年人中,毛细血管的内皮细胞分裂相对不佳,分裂速度通常为数月至数年。血管生成是一个通过多种类型的细胞与水溶性因子和细胞外基质(extracellular matrix)成分的相互作用而发生的复杂的过程。
当以这种方式严格调节的新生血管的生成过度进行时,会引起各种疾病。肿瘤中的新生血管对其他器官提供移动通道导致容易发生转移,不仅在肿瘤,而且在如年龄相关性黄斑变性(age-related macular degeneration)、糖尿病性视网膜病变(diabeticretinopathy)、早产儿视网膜病变(retinopathy of prematurity)、新生血管性青光眼(neovascular glaucoma)、牛皮癣(psoriasis)、类风湿关节炎(rheumatoid arthritis)或慢性炎症(chronicinflammation)等疾病起关键作用。
已知血管内皮生长因子(VEGF,Vascular endothelial growth factor)是在血管生成中起重要作用的因子,并且,已知所述VEGF可以通过称为HIF-1α(Hypoxia induciblefactor 1,alpha)的转录调节子(专利文献1)调节。
因此,需要开发一种HIF-1α抑制剂以及用于治疗、改善或预防与其相关的疾病或症状的技术。
发明内容
技术课题
本发明的目的在于,提供一种化合物,所述化合物优异地抑制HIF-1α而有效地用作用于预防或治疗新生血管相关性眼部疾病的药学组合物。
本发明的其他目的在于,提供一种所述化合物的制备方法。
本发明的其他另一目的在于,提供一种用于预防或治疗新生血管相关性眼部疾病的药学组合物,所述药学组合物包含所述化合物作为有效成分。
本发明的其他另一目的在于,提供一种用于预防或改善新生血管相关性眼部疾病的保健功能食品组合物,所述保健功能食品组合物包含所述化合物作为有效成分。
课题的解决方法
为了达成所述目的,本发明提供一种由以下化学式1表示的化合物、其的溶剂合物、水合物、旋光异构体或药学上可接受的盐:
[化学式1]
在所述化学式1中
A1和A2各自独立地为-H、-OH、-NO2、-CN、卤素、C1-10直链或支链烷基或C1-10直链或支链烷氧基;
B1为-H、-OH、-NO2、-CN、卤素、C1-10直链或支链烷基或C1-10直链或支链烷氧基;以及
R1为-H、-OH、-NO2、-CN、卤素、C1-10直链或支链烷基、C1-10直链或支链烷氧基、C3-10环烷氧基、二C1-10直链或支链烷基氨基、包含选自由N、O及S组成的组中的一种以上的杂原子的5至10元环的杂环烷基或未被取代或被一个以上的-CN取代的C6-10芳基C1-5烷基氨基。
另外,本发明提供所述化合物的制备方法。
进而,本发明的一具体例,提供一种用于预防或治疗新生血管相关性眼部疾病的药学组合物,所述药学组合物包含所述化合物作为有效成分。
另外,本发明的一具体例,提供一种用于预防或改善新生血管相关性眼部疾病的保健功能食品组合物,所述保健功能食品组合物包含所述化合物作为有效成分。
发明效果
本发明的一具体例提供的实施例化合物优异地抑制HIF-1α,因此可以有效地用作用于预防或治疗新生血管相关性眼部疾病的药学组合物。
附图说明
图1是示出评价根据本发明的一具体例的实施例化合物的新生血管抑制活性的结果的图表。
图2是示出评价根据本发明的一具体例的实施例化合物的HIF-1α(Hypoxia-Inducible Factor 1α)调节活性的结果的图表。
图3是示出评价根据本发明的一具体例的实施例化合物的因低氧而引起的视网膜新生血管抑制活性的结果的图表。
具体实施方式
本发明提供由以下化学式1表示的化合物、其的溶剂合物、水合物、旋光异构体或药学上可接受的盐:
[化学式1]
在化学式1中
A1和A2各自独立地为-H、-OH、-NO2、-CN、卤素、C1-10直链或支链烷基或C1-10直链或支链烷氧基;
B1为-H、-OH、-NO2、-CN、卤素、C1-10直链或支链烷基或C1-10直链或支链烷氧基;以及
R1为-H、-OH、-NO2、-CN、卤素、C1-10直链或支链烷基、C1-10直链或支链烷氧基、C3-10环烷氧基、二C1-10直链或支链烷基氨基、包含选自由N、O及S组成的组中的一种以上的杂原子的5至10元环的杂环烷基或未被取代或被一个以上的-CN取代的C6-10芳基C1-5烷基氨基。
在本发明的一具体例中,本发明提供化合物、其的溶剂合物、水合物、旋光异构体或药学上可接受的盐,其中在所述化学式1的化合物中,B1为C1-10直链或支链烷氧基,R1为包含选自由N、O及S组成的组中的一种以上的杂原子的5至10元环的杂环烷基或未被取代或被一个以上的-CN取代的C6-10芳基C1-5烷基氨基。
在本发明的一具体例中,本发明提供化合物、其的溶剂合物、水合物、旋光异构体或药学上可接受的盐,其中,在上述化学式1的化合物中,B1为C1-10直链或支链烷氧基,R1为包含N的5元环的杂环烷基或被一个以上的-CN取代的苄氨基。
实施方式
本发明的由所述化学式1表示的化合物可以作为药学上可接受的盐的形式来使用,其中盐优选通过药学上可接受的游离酸(free acid)来形成的酸加成盐。酸加成盐可以获得自:无机酸类,例如盐酸、硝酸、磷酸、硫酸、氢溴酸、氢碘酸、亚硝酸、及亚磷酸等;无毒性有机酸,例如脂族单/二羧酸、苯基取代的烷酸、羟基烷酸、烷二酸(alkandioate)、芳香族酸类、及脂族/芳香族磺酸类等;有机酸,例如三氟乙酸、乙酸、苯甲酸、柠檬酸、乳酸、马来酸、葡萄糖酸、甲磺酸、4-甲苯磺酸、酒石酸、及富马酸等。
所述药学上无毒性的盐的种类,包括硫酸盐、焦硫酸盐、硫酸氢盐、亚硫酸盐、亚硫酸氢盐、硝酸盐、磷酸盐、一氢磷酸盐、二氢磷酸盐、偏磷酸盐、焦磷酸盐氯化物、溴化物、碘化物、氟化物、乙酸盐、丙酸盐、癸酸盐、辛酸盐、丙烯酸盐、甲酸盐、异丁酸盐、癸酸盐、庚酸盐、丙炔酸盐、草酸盐、丙二酸盐、琥珀酸盐、辛二酸盐、癸二酸盐、延胡索酸盐、苹果酸盐、丁炔-1,4-二酸盐、己烷-1,6-二酸盐、苯甲酸盐、氯苯甲酸盐、甲基苯甲酸盐、二硝基苯甲酸盐、羟基苯甲酸盐、甲氧基苯甲酸盐、邻苯二甲酸盐、对苯二甲酸盐、苯磺酸盐、甲苯磺酸盐、氯苯磺酸盐、二甲苯磺酸盐、苯基乙酸盐、苯基丙酸盐、苯基丁酸盐、柠檬酸盐、乳酸盐、β-羟基丁酸、乙醇酸盐、苹果酸盐、酒石酸盐、甲磺酸盐、丙磺酸盐、萘-1-磺酸盐、萘-2-磺酸盐、及扁桃酸盐等。
根据本发明的酸加成盐可以通过常规的方法来制备,例如,将由化学式1表示的衍生物溶解在有机溶剂中,例如甲醇、乙醇、丙酮、二氯甲烷、乙腈等,过滤、干燥添加有机酸或无机酸而生成的沉淀物而制备酸加成盐,或将溶剂和过量的酸在减压下蒸馏后进行干燥,并在有机溶剂中结晶化即可制备。
另外,可以利用碱来制备药学上可接受的金属盐。碱金属或碱土金属盐通过以下过程来获得:例如,将化合物溶解在过量的碱金属氢氧化物或碱土金属氢氧化物溶液中,将不溶化合物盐过滤,并将残留溶液蒸发干燥而获得。此时,金属盐优选以钠、钾或钙盐的药物学适当的形式来制备。并且相应的盐通过将碱金属或碱土金属盐与适当的银盐(例如;硝酸银)反应而制备。
此外,本发明不仅包括由所述化学式1表示的化合物及其药学上可接受的盐,而且,包括可以由此制备的溶剂合物、旋光异构体、水合物等。
另外,本发明提供所述化合物的制备方法。
进而,在本发明的一具体例中,本发明提供一种用于预防或治疗新生血管相关性眼部疾病的药学组合物,其包含所述化合物作为有效成分。此时,作为几种具体例,所述新生血管相关性眼部疾病包括黄斑变性、视网膜静脉阻塞、糖尿病性视网膜病变、缺血性视网膜病变等,但不限于此。
由所述化学式1表示的化合物或其的药学上可接受的盐在临床给药时能够以口服及非口服的多种剂型给药。在制剂化的情况下,通过使用常规的填充剂、增量剂、结合剂、润湿剂、崩解剂、表面活性剂等的稀释剂或赋形剂来制备。用于口服给药的固体制剂包括片剂、丸剂、粉剂、颗粒剂、胶囊剂等,这种固体制剂对一种以上的化合物混合至少一种赋形剂而成,例如,混合淀粉、碳酸钙、蔗糖(sucrose)或乳糖(lactose)、明胶等来制备。并且,除了单纯的赋形剂以外,还可以使用硬脂酸镁、滑石等的润滑剂。作为用于口服给药的液相制剂相当于悬浮剂、内用水剂、油剂、糖浆等,并且除了通常使用的作为单纯稀释剂的水、液体石蜡以外,还包括多种赋形剂,例如,润湿剂、甜味剂、芳香剂、保鲜剂等。用于非口服给药的制剂包括灭菌的水溶液、非水性溶剂、悬浮剂、油剂。作为非水性溶剂、悬浮溶剂可使用丙二醇(propylene glycol)、聚乙二醇、橄榄油等的植物油、油酸乙酯等的可注射的酯等。
将由所述化学式1表示的化合物或其的药学上可接受的盐作为有效成分的药学组合物可以以非口服的方式给药,非口服的方式给药通过皮下注射、静脉内注射、肌肉注射或腹腔注射的方法。
此时,为了制剂化成非口服给药方式的剂型,将由所述化学式1表示的化合物或其的药学上可接受的盐与稳定剂或缓冲剂一起混合于水中制备溶液或悬浮液,并将其可以制备成单位制剂以安瓿或小瓶的形式施用。所述组合物经灭菌及/或可以含有防腐剂、稳定剂、可湿性粉剂或乳化促进剂、用于调整渗透压的盐及/或缓冲剂等的助剂及其它有用于治疗的物质,可以按照常规的混合、造粒或包衣的方法制剂化。
用于口服给药的制剂,例如可以包括片剂、丸剂、硬/软胶囊剂、液体制剂、悬浮剂、乳剂、糖浆剂、颗粒剂、酏剂、锭剂等,它们除了含有有效成分之外,还含有稀释剂(如乳糖、葡萄糖、蔗糖、甘露醇、山梨醇、纤维素及/或甘氨酸)、助流剂(如二氧化硅、滑石粉、硬脂酸及其镁或钙盐及/或聚乙二醇)。片剂可以含有粘合剂诸如硅酸镁铝、淀粉糊、明胶、甲基纤维素、羧甲基纤维素钠及/或聚乙烯吡咯烷酮等,并且必要时可以含有崩解剂诸如淀粉、琼脂、海藻酸或其钠盐等或共沸混合物及/或吸收剂、着色剂、芳香剂及甜味剂。
另外,在本发明的一具体例中,本发明提供一种用于预防或改善新生血管相关性眼部疾病的保健功能食品组合物,其包含所述化合物作为有效成分。
根据本发明的由所述化学式1表示的化合物可以原样添加到食品中,或者可以与其他食品或食品成分一起使用,并且可以根据常规方法适当地使用。有效成分的混合量可以根据使用目的(用于预防或改善)适当地决定。通常,保健食品中所述化合物的量可以以食品总重量的0.1至90重量份添加。但是,为了健康和卫生目的或健康调节目的而长期摄入的情况下,其含量可以小于上述范围,并且在安全性方面没有任何问题,因此可以以高于上述范围的量使用有效成分。
另外,本发明的保健功能性饮料组合物除了以指定比例含有所述化合物作为必要成分以外,对于其他成分没有特别限定,如普通饮料一样,作为附加成分可以含有各种香料和天然碳水化合物等。上述的天然碳水化合物,例如有单糖、二糖如葡萄糖和果糖等,多糖如麦芽糖和蔗糖等,普通的糖如糊精和环糊精等,以及糖醇如木糖醇、山梨醇、赤藓醇等。除了上面提到的香料之外,可以使用天然香料(索马甜、甜叶菊提取物(例如,莱鲍迪甙A,甘草甜素等))和合成香料(糖精、阿斯巴甜等)。对于所述天然碳水化合物的比率,通常对本发明的组合物每100g可以使用约1至20g,优选5至12g。
此外,除上述之外,根据本发明的由化学式1表示的化合物可包括各种营养剂、维生素、矿物质(电解质)、合成风味剂及和天然风味剂等的风味剂、着色剂及重质剂(奶酪、巧克力等)、果胶酸及其盐、海藻酸及其盐、有机酸、防护性胶质增稠剂、pH调节剂、稳定剂、防腐剂、甘油、醇类、用于碳酸饮料的碳化剂等。另外,由本发明的化学式1表示的化合物可以包含用于制备天然果汁和果汁饮料以及蔬菜饮料的果肉。
由于本发明的一具体例中提供的实施例化合物优异地抑制HIF-1α,因此,可以有效地用作用于预防或治疗新生血管相关性眼部疾病的药学组合物,这将由后述的实施例及实验例得到支持。
下面,通过实施例及实验例详细说明本发明。
但是,后述的实施例及实验例仅是本发明的例示,本发明不限于此。
<实施例1>2-(3,4-二甲氧基苯基)-1-(4-羟基-2-甲氧基苯基)乙烷-1-酮的制备(31)
向被溶解于甲醇的2-(3,4-二甲氧基苯基)-1-(2-甲氧基-4-(甲氧基甲氧基)苯基)乙烷-1-酮溶液(877mg,2.4mmol)添加2N-HCl溶液(10.0mL)。将反应混合物在60℃的温度下搅拌4小时后,用EtOAc提取。收集有机层,用盐水清洗后,经无水MgSO4干燥,并在减压下浓缩。并用硅胶快速柱层析(EtOAc/正己烷=1:1)纯化剩余物以制备标题化合物。
(723mg,94%)
1H-NMR(CDCl3,300MHz)δ7.71(d,J=8.7Hz,1H),6.79-6.71(m,3H),6.40-6.37(m,2H),5.52(s,1H),4.19(s,2H),3.86(s,3H),3.82(s,6H),3.82(s,3H).
<实施例2>1-(2,4-二甲氧基苯基)-2-(3,4-二甲氧基苯基)丙烷-1-酮的制备(32a)
在0℃的温度下,向被溶解于乙腈(1.0mL)的实施例1的化合物溶液中添加碳酸铯(52mg,0.2mmol)和碘甲烷(12.0μL,0.2mmol)。将反应混合物在0℃下搅拌20分钟,并在室温(约20至23℃)下搅拌1小时。用水处理反应混合物后结束反应,然后用EtOAc提取。收集有机层,用盐水清洗后,经无水MgSO4干燥,并在减压下浓缩。用硅胶快速柱层析(EtOAc/正己烷=1:2)纯化剩余物以制备黄色的油形态的标题化合物。(25mg,71%)
1H-NMR(CDCl3,500MHz)δ7.60(d,J=8.7Hz,1H),6.72(m,3H),6.42(dd,J=8.7,2.2Hz,1H),6.35(d,J=2.2Hz,1H),4.68(q,J=7.0Hz,1H),3.81(s,3H),3.80(s,3H),3.79(s,3H),1.44(d,J=7.0Hz,3H);13C-NMR(CDCl3,125MHz)δ201.8,163.9,159.8,148.7,147.6,134.6,132.8,121.5,120.2,111.2,111.0,104.9,98.3,55.8,55.7,55.4,55.3,50.6,19.1;HR-MS(ESI)calcd for C19H23O5(M+H+)331.1540,found 331.1537.
<实施例3>2-(3,4-二甲氧基苯基)-1-(4-乙氧基-2-甲氧基苯基)丙烷-1-酮的制备(32b)
使用碘乙烷(5.0μL,0.1mmol)来代替碘甲烷,除此之外,执行与实施例2类似的过程以制备浅黄色的油形态的标题化合物。(10mg,91%)
1H-NMR(CDCl3,800MHz)δ7.60(d,J=8.7Hz,1H),6.73(m,3H),6.41(dd,J=8.7,2.2Hz,1H),6.35(d,J=2.2Hz,1H),4.68(q,J=6.9Hz,1H),4.01(q,J=7.0Hz,1H),3.81(s,6H),3.80(s,3H),1.44(d,J=7.0Hz,3H),1.38(t,J=7.0Hz,3H);13C-NMR(CDCl3,200MHz)δ201.8,163.3,159.8,148.7,147.5,134.6,132.8,121.2,120.2,111.1,110.9,105.4,98.8,63.6,55.7,55.7,55.3,50.5,19.1,14.6;HR-MS(ESI)calcd for C20H25O5(M+H+)345.1697,found 345.1695.
<实施例4>1-(4-(环己氧基)-2-甲氧基苯基)-2-(3,4-二甲氧基苯基)丙烷-1-酮的制备(32c)
在被溶解于THF(1.0mL)的实施例1的化合物(26mg,0.1mmol)、环己醇(9μL,0.1mmol)及三苯膦(22mg,0.1mmol)溶液中添加溶解于THF(1.0mL)的偶氮二羧酸二乙酯(0.02mL,0.1mmol)。将反应混合物搅拌一天,并在减压下浓缩。并用硅胶柱层析(EtOAc/正己烷=1:6)纯化剩余物以制备无色的油形态的标题化合物。(42mg,43%)
1H-NMR(CDCl3,500MHz)δ7.59(d,J=8.7Hz,1H),6.73(m,3H),6.41(dd,J=8.7,2.1Hz,1H),6.34(d,J=2.1Hz,1H),4.69(q,J=6.9Hz,1H),4.26-4.22(m,1H),3.80(s,6H),3.79(s,3H),1.96-1.90(m,2H),1.79-1.73(m,2H),1.54-1.46(m,2H),1.33-1.27(m,4H);13C-NMR(CDCl3,125MHz)δ201.7,162.4,160.0,148.8,147.6,134.7,132.8,121.0,120.2,111.2,111.0,106.3,100.0,75.4,55.8(two carbons),55.3,50.5,31.7,31.6,25.4,23.6(two carbons),19.2;HR-MS(ESI)calcd for C24H31O5(M+H+)399.2166,found 399.2164.
<实施例5>2-(3,4-二甲氧基苯基)-1-(4-(二甲基氨基)-2-甲氧基苯基)丙烷-1-酮的制备(34a)
对4-(2-(3,4-二甲氧基苯基)丙酰基)-3-甲氧基苯基三氟甲磺酸酯(20mg,0.04mmol)处理二甲胺(2.0M THF溶液,0.23mL,0.5mmol)进行胺化,并用硅胶快速柱层析(EtOAc/正己烷=1:3至1:1)纯化以制备黄色的油形态的标题化合物。(6mg,41%)
1H-NMR(CDCl3,800MHz)δ7.71(d,J=8.9Hz,1H),6.79(s,1H),6.78(d,J=8.2Hz,1H),6.72(d,J=8.2Hz,1H),6.22(dd,J=8.9,2.2Hz,1H),5.98(d,J=2.0Hz,1H),4.74(q,J=7.0Hz,1H),3.82(s,3H),3.81(s,3H),3.79(s,3H),2.99(s,6H),1.42(d,J=7.0Hz,3H);13C-NMR(CDCl3,200MHz)δ200.3,160.7,154.4,148.6,147.3,135.6,133.2,120.1,115.9,111.1,110.9,104.3,93.8,55.7(two carbons),54.9,50.0,40.0(two carbons),19.6;HR-MS(ESI)calcd for C20H26NO4(M+H+)344.1856,found 344.1860.
<实施例6>2-(3,4-二甲氧基苯基)-1-(2-甲氧基-4-(吡咯烷-1-基)苯基)丙烷-1-酮的制备(34b)
对4-(2-(3,4-二甲氧基苯基)丙酰基)-3-甲氧基苯基三氟甲磺酸酯(20mg,0.04mmol)处理吡咯烷(7μL,0.1mmol)进行胺化,并用硅胶快速柱层析(EtOAc/正己烷=1:2至1:1)纯化以制备浅黄色形态的标题化合物。(19mg,90%)
1H NMR(CDCl3,300MHz)δ7.67(dd,J=8.7,1.2Hz,1H),6.75-6.65(m,3H),6.04(dd,J=8.7,2.0Hz,1H),5.79(s,1H),4.69(q,J=6.9Hz,1H),3.77-3.72(m,9H),3.24-3.22(m,4H),1.97-1.90(m,4H),1.37(d,3H,J=6.9Hz);13C NMR(CDCl3,200MHz)δ200.1,160.9,152.0,148.6,147.3,135.7,133.4,120.1,115.3,111.1,110.9,104.4,93.6,55.7(twocarbons),54.9,49.9,47.5(two carbons),25.3(two carbons),19.7;HR-MS(FAB)calcdfor C22H28NO4(M+H+)370.2018,found 370.2032.
<实施例7>2-(3,4-二甲氧基苯基)-1-(2-甲氧基-4-(哌啶-1-基)苯基)丙烷-1-酮的制备(34c)
对4-(2-(3,4-二甲氧基苯基)丙酰基)-3-甲氧基苯基三氟甲烷磺酸酯(20mg,0.04mmol)处理哌啶(8μL,0.1mmol)进行胺化,并用硅胶快速柱层析(EtOAc/正己烷=1:2)纯化以制备浅黄色的油形态的标题化合物。(10mg,45%)
1H-NMR(CDCl3,300MHz)δ7.61(d,J=8.7Hz,1H),6.73-6.65(m,3H),6.35(dd,J=8.7,2.1Hz,1H),6.16(d,J=1.8Hz,1H),4.67(q,J=6.9Hz,1H),3.76(s,6H),3.75(s,3H),3.21-3.20(m,4H),1.65-1.60(m,6H),1.37(d,3H,J=6.9Hz);13C NMR(CDCl3,200MHz)δ200.5,160.4,155.5,148.6,147.3,135.3,133.0,120.1,117.4,111.1,110.9,106.8,96.8,55.7(two carbons),55.0,50.1,48.8(two carbons),25.4(two carbons),24.3,19.5;HR-MS(FAB)calcd for C23H30NO4(M+H+)384.2175,found 384.2170.
<实施例8>2-(3,4-二甲氧基苯基)-1-(2-甲氧基-4-吗啉代苯基)丙烷-1-酮的制备(34d)
对4-(2-(3,4-二甲氧基苯基)丙酰基)-3-甲氧基苯基三氟甲磺酸酯(20mg,0.04mmol)处理吗啉(4mg,0.04mmol)进行胺化,并用硅胶快速柱层析(EtOAc/正己烷=1:2至2:1)纯化以制备黄色的油形态的标题化合物。(7mg,53%)
1H-NMR(CDCl3,800MHz)δ7.65(d,J=8.8Hz,1H),6.75(m,2H),6.72(d,,J=8.0Hz,1H),6.40(dd,J=8.9,2.2Hz,1H),6.23(d,J=2.2Hz,1H),4.70(q,J=6.9Hz,1H),3.82(s,3H),3.90-3.70(m,10H),3.22(dd,J=5.9,3.9Hz,4H),1.43(d,J=7.0Hz,3H);13C-NMR(CDCl3,200MHz)δ200.9,160.1,155.2,148.7,147.4,135.0,132.9,120.2,119.0,111.1,110.9,106.6,96.9,66.5(two carbons),55.7,55.7,55.1,50.3,47.7(two carbons),19.4;HR-MS(ESI)calcd for C22H28NO5(M+H+)386.1962,found 386.1963.
<实施例9>1-(4-(苄氨基)-2-甲氧基苯基)-2-(3,4-二甲氧基苯基)丙烷-1-酮的制备(34e)
对4-(2-(3,4-二甲氧基苯基)丙酰基)-3-甲氧基苯基三氟甲磺酸酯(20mg,0.04mmol)处理苄胺(0.01mL,0.084mmol)进行胺化,并用硅胶快速柱层析(EtOAc/正己烷=1:2)纯化以制备黄色的油形态的标题化合物。(20mg,88%)
1H-NMR(Acetone-d6,300MHz)δ7.55(d,1H,J=8.6Hz),7.39-7.36(m,2H),7.33-7.28(m,2H),7.22(m,1H),6.86(d,1H,J=1.8Hz),6.78-6.70(m,2H),6.26-6.18(m,3H),4.78(q,1H,J=6.9Hz),4.40(d,2H,J=5.6Hz),3.79(s,3H),3.74(s,3H),3.71(s,3H),1.33(d,3H,J=6.9Hz);13C-NMR(CDCl3,200MHz)δ200.4,160.8,152.9,148.7,147.4,138.3,135.4,133.5,128.8(two carbons),127.5,127.4(two carbons),120.1,117.4,111.2,110.9,105.1,94.7,55.8(two carbons),55,50,47.7,19.6;HRMS(FAB)calcd for C25H28NO4(M+H+):406.2018,Found:406.2024.
<实施例10>4-(((4-(2-(3,4-二甲氧基苯基)丙酰基)苯基)氨基)甲基)苄腈的制备(34f)
对4-(2-(3,4-二甲氧基苯基)丙酰基)-3-甲氧基苯基三氟甲磺酸酯(20mg,0.04mmol)处理4-氰基苄胺(10.8mg,0.082mmol)进行胺化,并用硅胶快速柱层析(EtOAc/正己烷=1:2)纯化以制备黄色的油形态的标题化合物。(16mg,91%)
1H-NMR(CDCl3,800MHz)δ7.61(d,1H,J=8.6Hz),7.60(d,2H,J=8.2Hz),7.41(d,2H,J=8.2Hz),6.76(s,1H),6.74(d,1H,J=1.9Hz),6.72(d,1H,J=8.0Hz),6.10(dd,1H,J=8.6,2.2Hz),5.94(d,1H,J=2.1Hz),4.68(q,1H,J=7.0Hz),4.58(t,1H,J=5.8Hz),4.42(d,2H,J=5.8Hz),3.80(s,3H),3.80(s,3H),3.72(s,3H),1.41(d,3H,J=7.0Hz);13C-NMR(CDCl3,200MHz)δ200.6,160.6,152.2,148.7,147.4,144.1,135.2,133.6,132.6(twocarbons),127.6(two carbons),120.2,118.6,118.1,111.4,111.2,110.9,105.0,95.1,55.8(two carbons),55.0,50.2,47.2,19.6;HRMS(ESI)calcd for C26H26N2O4(M+H+):430.1893,Found:430.1887.
<实施例11>2-(3,4-二甲氧基苯基)-1-(4-(吡咯烷-1-基)苯基)丙烷-1-酮的制备(37a)
对1-(4-溴苯基)-2-(3,4-二甲氧基苯基)丙烷-1-酮(23mg,0.1mmol)处理吡咯烷(15μL,0.2mmol)进行胺化,并用硅胶快速柱层析(EtOAc/正己烷=1:6)纯化以制备浅黄色的油形态的标题化合物。(11mg,57%)
1H-NMR(CDCl3,500MHz)δ7.87(d,J=8.9Hz,2H),6.83(dd,J=8.1,1.8Hz,1H),6.79(d,J=1.8Hz,1H),6.74(d,J=8.2Hz,1H),6.42(d,J=8.9Hz,2H),4.55(q,J=6.8Hz,1H),3.82(s,3H),3.79(s,3H),3.29(t,J=6.6Hz,4H),2.00-1.96(m,4H),1.46(d,J=6.8Hz,3H);13CNMR(CDCl3,125MHz)δ198.4,150.7,149.0,147.6,135.3,131.0,131.0,123.8,119.8,111.3,110.6,110.6,110.5,55.8,55.8,47.4,47.4,46.2,25.3,25.3,19.6.;HR-MS(FAB)calcd for C21H26NO3(M+H+)340.1913,found 340.1904.
<实施例12>2-(3,4-二甲氧基苯基)-1-(4-吗啉代苯基)丙烷-1-酮的制备(37b)
对1-(4-溴苯基)-2-(3,4-二甲氧基苯基)丙烷-1-酮(23mg,0.1mmol)处理吗啉(5mg,0.1mmol)进行胺化,并用硅胶快速柱层析(EtOAc/正己烷=1:2至1:1)纯化以制备黄色的油形态的标题化合物。(12mg,80%)
1H-NMR(CDCl3,800MHz)δ7.88(d,J=9.1Hz,2H),6.81(dd,J=8.2,2.1Hz,1H),6.76(m,4H),4.54(q,J=6.8Hz,1H),3.82(s,3H),3.79(s,6H),3.23(t,J=5.0Hz,4H),1.45(d,J=6.9Hz,3H);13C-NMR(CDCl3,200MHz)δ198.7,153.9,149.1,147.7,134.7,130.7(twocarbons),127.1,119.9,113.2(two carbons),111.3,110.5,66.5(two carbons),55.8,55.8,47.4(two carbons),46.7,19.5;HR-MS(ESI)calcd for C21H26NO4(M+H+)356.1856,found 356.1851.
<实施例13>2-(2-氟苯基)-1-(4-(哌啶-1-基)苯基)丙烷-1-酮的制备(41a)
对1-(4-溴苯基)-2-(2-氟苯基)丙烷-1-酮(31mg,0.1mmol)处理哌啶(15μL,0.2mmol)进行胺化,并用硅胶快速柱层析(EtOAc/正己烷=1:5)纯化以制备黄色的固体形态的标题化合物。(24mg,68%)
1H-NMR(CDCl3,800MHz)δ7.85(d,2H,J=9.0Hz),7.24-7.22(m,1H),7.15-7.12(m,1H),7.02(d,1H,J=8.3Hz),7.01(d,1H,J=8.2Hz),6.76(d,2H,J=9.0Hz),4.96(q,1H,J=6.9Hz),3.30(s,4H),1.61(s,6H),1.47(d,3H,J=6.9Hz);13C-NMR(CDCl3,200MHz)δ197.8,159.6(d,JC-F=243Hz),154.2,130.7,129.3,129.2,128.9(d,JC-F=3.9Hz),128.2,128.1,125.2,124.5(d,JC-F=3.3Hz),115.4(d,JC-F=22.5Hz),113.2,48.4,38.4,38.4,25.3(two carbons),24.3,18.2;
<实施例14>1-(4-(苄氨基)苯基)-2-(2-氟苯基)丙烷-1-酮的制备(41b)
对1-(4-溴苯基)-2-(2-氟苯基)丙烷-1-酮(24mg,0.1mmol)处理吗啉(13μL,0.1mmol)进行胺化,并用硅胶快速柱层析(EtOAc/正己烷=1:5)纯化以制备白色的固体形态的标题化合物。(18mg,71%)
1H-NMR(CDCl3,600MHz)δ7.83-7.82(m,2H),7.33-7.25(m,5H),7.22-7.21(m,2H),7.15-7.12(m,2H),7.02-6.99(m,2H),6.52-6.51(m,2H),4.94(q,1H,J=8.6Hz),4.53(broad,1H),4.33(s,2H),1.46(d,3H,J=6.9Hz);13C-NMR(CDCl3,150MHz)δ197.7,159.6(d,JC-F=243Hz),151.8,138.1,131.0,131.0,129.2(d,JC-F=15.0Hz),128.8(d,JC-F=4.3Hz),128.7,128.7,128.1(d,JC-F=7.8Hz),127.5,127.3,127.3,125.6,124.5,(d,JC-F=3.5Hz),115.3(d,JC-F=22.2Hz),111.6,111.6,47.5,38.3(d,JC-F=2.1Hz),18.2;HRMS(ESI)calcd for C22H21FNO(M+H+):334.1607,Found:334.1611.
<实施例15>2-(2-氟苯基)-1-(2-甲氧基-4-(哌啶-1-基)苯基)丙烷-1-酮的制备
LR-MS(ESI)calcd for C21H25FNO2(M+H+)342.4,found 342.4.
<实施例16>4-(((4-(2-(2-氟苯基)丙酰基)-3-甲氧基苯基)氨基)甲基)苄腈的制备
LR-MS(ESI)calcd for C24H22FN2O2(M+H+)389.4,found 389.4
整理实施例1至16的化合物的结构并示于下表1中。
【表1】
<比较例1>SH-1242(2)化合物的制备
参照J.Mol.Med.(Berl.)2014,92,1083-1092文献(Hypoxia-mediated retinalneovascularization and vascular leakage in diabetic retina is suppressed byHIF-1αdestabilization by SH-1242and SH-1280,novel hsp90 inhibitors)准备比较例1的化合物。
<实验例1>评价HIF-1α抑制活性(体外(in vitro))
为了评价根据本发明的一具体例的实施例化合物的HIF-1α(Hypoxia-InducibleFactor 1α)抑制活性,进行了以下实验。
将其结果示于下表2。
【表2】
实施例 | IC50(μM) |
1 | >15 |
2 | >15 |
3 | 11.68 |
4 | 2.59 |
5 | >15 |
6 | 2.82 |
7 | 1.85 |
8 | 8.74 |
9 | 1.43 |
10 | 0.60 |
11 | 2.61 |
12 | 6.85 |
13 | 2.06 |
14 | 7.35 |
15 | 6.52 |
16 | 5.28 |
如上述表2所示,确认到根据本发明的一具体例的实施例化合物优异地抑制HIF-1α(Hypoxia-Inducible Factor 1α)。尤其,确认到实施例化合物中,实施例10的化合物具有最优异的抑制活性。
<实验例2>评价新生血管抑制活性(体外(in vitro))
为了评价根据本发明的一具体例的实施例化合物的新生血管抑制活性,进行了以下实验。
将其结果示于图1。
图1是示出评价根据本发明的一具体例的实施例化合物的新生血管抑制活性的结果的图表,在图1中,2化合物是对比例1的化合物,34f化合物是实施例10的化合物。
如图1所示,确认到本发明的实施例10的化合物与对比例1的化合物相比相对具有优异的新生血管抑制活性。
<实验例3>HIF-1α调节活性的评价(体外(in vitro))
为了评价根据本发明的一具体例的实施例化合物的HIF-1α(Hypoxia-InducibleFactor 1α)调节活性,进行了以下实验。
将其结果示于图2。
图2是示出评价根据本发明的一具体例的实施例化合物的HIF-1α(Hypoxia-Inducible Factor 1α)调节活性的结果的图表,图2中2化合物是对比例1的化合物,34f化合物是实施例10的化合物。
如图2所示,确认到本发明的实施例10的化合物与对比例1的化合物相比相对具有优异的HIF-1α调节活性。
<实验例4>评价因缺氧引起的视网膜新生血管抑制活性
为了评价根据本发明的一具体例的实施例化合物的因缺氧引起的视网膜新生血管抑制活性,进行了以下实验。
将其结果示于图3。
图3是显示根据本发明的一具体例的实施例化合物的因缺氧而引起的视网膜新生血管的抑制活性的结果的图表,图3中2化合物是对比例1的化合物,34f化合物是实施例10的化合物。
如图3所示,确认到本发明的实施例10的化合物与对比例1的化合物相比相对更好地抑制因缺氧而引起的视网膜新生血管。
<制剂例1>药学制剂的制备
1-1.粉剂的制备
化学式1的化合物 500mg
乳糖 100mg
滑石粉 10mg
将上述成分混合填充到密封包装中以制备粉剂。
1-2.片剂的制备
将上述成分混合并用常规的方法压片制成片剂。
1-3.胶囊的制备
根据常规的胶囊制备方法混合上述的成分并填充到明胶胶囊中制成胶囊剂。
1-4.注射剂的制备
化学式1的化合物 500mg
注射用灭菌蒸馏水 适量
pH调节剂 适量
根据常规的注射剂的制备方法,每安瓿瓶(2ml)中使用上述的成分含量。
1-5.液剂的制备
根据常规的液剂制备方法对纯净水添加各成分并使其溶解,添加适量柠檬香后混合上述成分,然后,加入纯净水,将总量调节至100mL,然后填充至棕色瓶进行灭菌制备液体。
Claims (11)
1.一种由以下化学式1表示的化合物、其的溶剂合物、水合物、旋光异构体或药学上可接受的盐:
[化学式1]
在所述化学式1中,
A1和A2各自独立地为-H、-OH、-NO2、-CN、卤素、C1-10直链或支链烷基或C1-10直链或支链烷氧基;
B1为-H、-OH、-NO2、-CN、卤素、C1-10直链或支链烷基或C1-10直链或支链烷氧基;以及
R1为-H、-OH、-NO2、-CN、卤素、C1-10直链或支链烷基、C1-10直链或支链烷氧基、C3-10环烷氧基、二C1-10直链或支链烷基氨基、包含选自由N、O及S组成的组中的一种以上的杂原子的5至10元环的杂环烷基或未被取代或被一个以上的-CN取代的C6-10芳基C1-5烷基氨基。
2.根据权利要求1所述的化合物、其的溶剂合物、水合物、旋光异构体或药学上可接受的盐,其特征在于,B1为C1-10直链或支链烷氧基,R1为包含选自由N、O及S组成的组中的一种以上的杂原子的5至10元环的杂环烷基或未被取代或被一个以上的-CN取代的C6-10芳基C1-5烷基氨基。
3.根据权利要求2所述的化合物、其的溶剂合物、水合物、旋光异构体或药学上可接受的盐,其特征在于,B1为C1-10直链或支链烷氧基,R1为包含N的5元环的杂环烷基或被一个以上的-CN取代的苄氨基。
5.一种药学组合物,其特征在于,包含权利要求1的化合物、化合物、其的溶剂合物、水合物、旋光异构体或药学上可接受的盐、以及药学上可接受的稀释剂或载体。
6.一种药学组合物,其特征在于,包含权利要求4的化合物、其的药学上可接受的盐或溶剂合物、以及药学上可接受的稀释剂或载体。
7.一种在试样或细胞中抑制HIF-1α的方法,其特征在于,包括对试样施用药学有效量的权利要求1的化合物。
8.一种在试样治疗或预防新生血管相关性眼部疾病的方法,其特征在于,包括向试样施用药学有效量的权利要求1的化合物。
9.根据权利要求8所述的方法,其特征在于,所述新生血管相关性眼部疾病是年龄相关性黄斑变性、糖尿病性视网膜病变,早产儿视网膜病变或新生血管性青光眼。
10.根据权利要求5所述的药学组合物,其特征在于,所述药学组合物用于预防或治疗新生血管相关性眼部疾病。
11.根据权利要求10所述的药学组合物,其特征在于,所述新生血管相关性眼部疾病是年龄相关性黄斑变性、糖尿病性视网膜病变,早产儿视网膜病变或新生血管性青光眼。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2018-0103985 | 2018-08-31 | ||
KR20180103985 | 2018-08-31 | ||
KR10-2019-0096669 | 2019-08-08 | ||
KR1020190096669A KR102527205B1 (ko) | 2018-08-31 | 2019-08-08 | 신규한 HIF-1α 억제제, 이의 제조방법 및 이를 유효성분으로 함유하는 신생혈관 관련 안질환의 예방 또는 치료용 약학적 조성물 |
PCT/KR2019/010208 WO2020045856A1 (ko) | 2018-08-31 | 2019-08-12 | 신규한 HIF-1α 억제제, 이의 제조방법 및 이를 유효성분으로 함유하는 신생혈관 관련 안질환의 예방 또는 치료용 약학적 조성물 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112166099A true CN112166099A (zh) | 2021-01-01 |
CN112166099B CN112166099B (zh) | 2023-08-01 |
Family
ID=69809756
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201980035213.9A Active CN112166099B (zh) | 2018-08-31 | 2019-08-12 | HIF-1α抑制剂以及包含其的药学组合物 |
Country Status (11)
Country | Link |
---|---|
US (1) | US12006283B2 (zh) |
EP (1) | EP3845516A4 (zh) |
JP (1) | JP7099754B2 (zh) |
KR (1) | KR102527205B1 (zh) |
CN (1) | CN112166099B (zh) |
AU (1) | AU2019332477B2 (zh) |
BR (1) | BR112020024110A2 (zh) |
CA (1) | CA3101977C (zh) |
MX (1) | MX2020012609A (zh) |
RU (1) | RU2770027C1 (zh) |
SA (1) | SA520420687B1 (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102527205B1 (ko) | 2018-08-31 | 2023-05-03 | 서울대학교산학협력단 | 신규한 HIF-1α 억제제, 이의 제조방법 및 이를 유효성분으로 함유하는 신생혈관 관련 안질환의 예방 또는 치료용 약학적 조성물 |
WO2023287251A1 (ko) * | 2021-07-16 | 2023-01-19 | 주식회사 노벨티노빌리티 | Hif-1 알파 저해제 |
CN114989085B (zh) * | 2022-05-23 | 2023-11-24 | 安徽医科大学 | 一种芳基内酰胺环类化合物、药物组合物及其应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1575289A (zh) * | 2001-10-25 | 2005-02-02 | 诺沃根研究有限公司 | 6-羟基异黄酮、及其衍生物和相关药物 |
KR20170033104A (ko) * | 2015-09-16 | 2017-03-24 | 서울대학교산학협력단 | 생체 시계 조절용 화합물 및 이의 용도 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100305068A1 (en) * | 2006-11-09 | 2010-12-02 | Foldrx Pharmaceuticals, Inc. | Compounds and methods for modulating protein trafficking |
KR101062367B1 (ko) | 2009-03-12 | 2011-09-05 | 웅진코웨이주식회사 | 배뇨 채취 장치 |
CN102675366B (zh) | 2012-05-10 | 2015-09-30 | 浙江大学 | 2-烷氧基-6-氨基苯基二烷基膦及其合成和应用 |
WO2014007412A1 (ko) | 2012-07-04 | 2014-01-09 | 서울대학교 산학협력단 | 신규한 화합물 또는 이의 약학적으로 허용가능한 염 및 이를 유효성분으로 함유하는 약학적 조성물 |
US20180132516A1 (en) * | 2016-11-16 | 2018-05-17 | Sensorygen, Inc. | Positive allosteric modulators of sweet taste |
WO2020045856A1 (ko) | 2018-08-31 | 2020-03-05 | 서울대학교 산학협력단 | 신규한 HIF-1α 억제제, 이의 제조방법 및 이를 유효성분으로 함유하는 신생혈관 관련 안질환의 예방 또는 치료용 약학적 조성물 |
KR102527205B1 (ko) | 2018-08-31 | 2023-05-03 | 서울대학교산학협력단 | 신규한 HIF-1α 억제제, 이의 제조방법 및 이를 유효성분으로 함유하는 신생혈관 관련 안질환의 예방 또는 치료용 약학적 조성물 |
-
2019
- 2019-08-08 KR KR1020190096669A patent/KR102527205B1/ko active IP Right Grant
- 2019-08-12 BR BR112020024110-5A patent/BR112020024110A2/pt active Search and Examination
- 2019-08-12 RU RU2020137660A patent/RU2770027C1/ru active
- 2019-08-12 AU AU2019332477A patent/AU2019332477B2/en active Active
- 2019-08-12 MX MX2020012609A patent/MX2020012609A/es unknown
- 2019-08-12 EP EP19856396.7A patent/EP3845516A4/en active Pending
- 2019-08-12 CN CN201980035213.9A patent/CN112166099B/zh active Active
- 2019-08-12 JP JP2020564862A patent/JP7099754B2/ja active Active
- 2019-08-12 CA CA3101977A patent/CA3101977C/en active Active
- 2019-08-12 US US17/057,297 patent/US12006283B2/en active Active
-
2020
- 2020-11-30 SA SA520420687A patent/SA520420687B1/ar unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1575289A (zh) * | 2001-10-25 | 2005-02-02 | 诺沃根研究有限公司 | 6-羟基异黄酮、及其衍生物和相关药物 |
KR20170033104A (ko) * | 2015-09-16 | 2017-03-24 | 서울대학교산학협력단 | 생체 시계 조절용 화합물 및 이의 용도 |
Non-Patent Citations (1)
Title |
---|
HYO JEONG HONG AND JAE IN LEE: "A Versatile Synthesis of O-Desmethylangolensin Analogues from Methoxy-Substituted Benzoic Acids", 《JOURNAL OF THE KOREAN CHEMICAL SOCIETY》 * |
Also Published As
Publication number | Publication date |
---|---|
SA520420687B1 (ar) | 2023-02-26 |
EP3845516A4 (en) | 2022-06-08 |
JP7099754B2 (ja) | 2022-07-12 |
CN112166099B (zh) | 2023-08-01 |
RU2770027C1 (ru) | 2022-04-14 |
BR112020024110A2 (pt) | 2021-03-09 |
AU2019332477B2 (en) | 2022-06-30 |
CA3101977C (en) | 2023-04-11 |
CA3101977A1 (en) | 2020-03-05 |
US12006283B2 (en) | 2024-06-11 |
AU2019332477A1 (en) | 2020-12-10 |
JP2021523927A (ja) | 2021-09-09 |
US20210188753A1 (en) | 2021-06-24 |
KR102527205B1 (ko) | 2023-05-03 |
KR20200026699A (ko) | 2020-03-11 |
MX2020012609A (es) | 2021-02-26 |
EP3845516A1 (en) | 2021-07-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN112166099B (zh) | HIF-1α抑制剂以及包含其的药学组合物 | |
KR102382188B1 (ko) | NamPT 억제용 신규 화합물 및 이를 포함하는 조성물 | |
JP6890805B2 (ja) | S1pr4をターゲットとする非アルコール性脂肪肝炎の予防または治療用組成物 | |
EP2725018A1 (en) | Substituted cinnamamide derivative, preparation method and use thereof | |
TW202304864A (zh) | 1,3-取代的環丁基衍生物及其用途 | |
JP2012500222A (ja) | 金属酵素阻害剤の設計および開発のための組成物および方法 | |
KR102174395B1 (ko) | 쿠마린-3-카복시아마이드 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 유로텐신-ⅱ 수용체 활성 관련 질환의 예방 또는 치료용 약학적 조성물 | |
KR20230098496A (ko) | 수면 개선용 신규 화합물 내지 이의 용도 | |
US20140031563A1 (en) | New compounds for inhibiting differentiation of osteoclast and pharmaceutical composition comprising thereof | |
KR102085758B1 (ko) | 히스톤 아세틸트렌스퍼라제 p300 억제용 신규 화합물 및 이를 포함하는 항섬유화 조성물 | |
KR102176621B1 (ko) | 페닐피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 글루카곤 수용체 활성 관련 질환의 예방 또는 치료용 약학적 조성물 | |
WO2016191316A1 (en) | Modulation of drug-induced cardiotoxicity | |
US20220194911A1 (en) | Novel compound for inhibiting histone acetyltransferase p300 and antifibrotic composition comprising same | |
EP4011862A1 (en) | Novel compound for inhibiting histone acetyltransferase p300 and anti-fibrosis composition comprising same | |
JP2023506119A (ja) | 神経因性疼痛の治療におけるフェニルキノリノン系誘導体およびフラボノイド系誘導体の使用 | |
EP4095133B1 (en) | Benzimidazolone-based cinnamamide derivative as trpv1 antagonist and pharmaceutical composition for treatment or prevention of pain containing same as active ingredient | |
KR101467673B1 (ko) | 신규한 페놀산 유도체 및 이의 항산화제로서의 용도 | |
KR20230072436A (ko) | 신규한 카나비크로멘산 유도체, 이의 제조방법 및 이를 포함하는 인지기능 개선용 조성물 | |
KR20220047168A (ko) | Pcsk9 억제제로서 아미노알콜 유도체 및 이를 함유하는 고콜레스테롤 혈증의 예방 또는 치료용 약학적 조성물 | |
KR20200081313A (ko) | 세포 내 atp 생성 촉진을 위한 약제학적 조성물 | |
EA016869B1 (ru) | КОМБИНАЦИЯ ПРОИЗВОДНЫХ ТРИАЗИНА И АГОНИСТОВ PPARα | |
NZ618801B2 (en) | Substituted cinnamamide derivative, preparation method and use thereof | |
KR20070015639A (ko) | 함질소환 화합물 및 이들을 포함하는 의약 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |